Key result
Botulinum toxin type A reduces post-stroke upper limb spasticity and improves basic functional activities.
Answers are grounded in this paper and cite their sources.
Spasticity is involuntary overactivity of muscles that occurs following upper motor neuron damage to the brain or spinal cord. Upper limb spasticity is common after stroke and can cause deformity, pain and reduced function. Botulinum toxin type A is a neurotoxin produced by the bacterium Clostridium botulinum that blocks the release of acetylcholine from cholinergic neurons. When given by intramuscular injection it causes temporary local paresis and has become an important component of focal spasticity treatment. Randomized controlled trials have shown that botulinum toxin type A can decrease upper limb spasticity and improve the ease of performing basic upper limb functional activities, such as cleaning the hand or dressing a sleeve. This article will review the pharmacology of botulinum toxin type A and its clinical efficacy when used to treat upper limb spasticity after stroke.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (2009) conducted a review in Upper limb spasticity after stroke. Botulinum toxin type A was evaluated on Upper limb spasticity and ease of performing basic upper limb functional activities. Botulinum toxin type A intramuscular injections decrease upper limb spasticity and improve basic upper limb functional activities after stroke in randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: